Au is the founder and chief executive of Regencell, a developer of traditional Chinese medicine for the treatment of autism and other neurocognitive disorders. The Hong Kong-based company is publicly traded in the US and its market capitalization rose above $30 billion in June 2025 despite not having generated any revenue.
Au's fortune is derived from his stake in Regencell Bioscience Holdings Limited, a traditional Chinese medicine company that trades publicly in the US. The Hong Kong-based firm generated a loss of $4.7 million in the year to June 30, 2024, and has never turned a yearly profit since its US listing in 2021.
He owns about 89% of the company's stock through holding company Regencell (BVI) Limited, according to a March 2026 Form 3 filing. Shares held by his spouse are also included in the valuation.
The company didn't respond to requests for comment on the net worth calculation.
Au was born in the early 1970s. He suffered from autism and attention deficit hyperactivity disorder as a child, which led to early struggles at school. He credits traditional Chinese medicine with improving his health and graduated from Haas School of Business at UC Berkeley.
He worked in investment banking and was involved in over $4 billion in deals, according to the Regencell website.
Regencell was founded in 2014 to produce herbal medicines. It has the exclusive rights of the formulas developed by Au's father, Sik-Kee Au.
The company became publicly traded in the US in 2021 and its stock surged in 2025, giving Regencell a valuation of more than $30 billion despite it never having sold any product.